BioNTech, Gilead to test drug combination in advanced breast cancer trial 

By Reuters News

Oct 22 (Reuters) - Germany's BioNTech 22UAy.DE said on Thursday it had teamed up with Gilead Sciences GILD.O to test its experimental cancer therapy in combination with the US drugmaker's approved treatment in patients with a form of advanced breast cancer.

Here are some details:

  • The late-stage trial will test BioNTech's pumitamig with Gilead's FDA-approved Trodelvy in patients with triple-negative breast cancer

  • BioNTech plans to update its late-stage study to compare the combination against treatment with Trodelvy alone, replacing its earlier plan to test pumitamig plus chemotherapy against chemotherapy

  • The safety and effectiveness of the combination has not been established, and the planned trial changes would require approval from health regulators, BioNTech said

  • Triple-negative breast cancer is an aggressive form of the disease that lacks common treatment targets and accounts for about 10% to 15% of breast cancer cases, according to BioNTech

  • The study will include patients with locally advanced or metastatic triple-negative breast cancer whose tumors have low or no levels of PD-L1, a biomarker used to guide treatment

  • BioNTech will sponsor and lead the trial, while Gilead will supply Trodelvy

  • Pumitamig is being developed by BioNTech and Bristol Myers Squibb BMY.N and is central to their $11.1 billion collaboratio signed in 2025

  • The drug is designed to help the immune system attack cancer cells and limit blood supply to tumors

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.